http://ift.tt/eA8V8J
Astellas Pharma will acquire Ogeda SA and its lead investigational candidate, fezolinetant, for the non-hormonal treatment of menopause-related vasomotor symptoms ("MR-VMS").
April 04, 2017 at 02:59AM
http://ift.tt/2ov48N0
from
http://ift.tt/2ov48N0
Featured Post
Twenty Practical Steps to Better Corporate Governance | The Corporate Secretaries International Association (CSIA)
Twenty Practical Steps to Better Corporate Governance | The Corporate Secretaries International Association (CSIA) Please click the li...
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment